• Symbol: MNTR

Mentor Capital, Inc.
  • Home
  • About Us
    • About
    • Professional Support
    • Management Team
    • Board of Directors
  • Media
  • Portfolio & Investments
  • Investors Corner
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Press
  • FAQ
  • Contact
    • Contact Us
    • Funding Application
Mentor Capital, Inc.
  • Home
  • About Us
    • About
    • Professional Support
    • Management Team
    • Board of Directors
  • Media
  • Portfolio & Investments
  • Investors Corner
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Press
  • FAQ
  • Contact
    • Contact Us
    • Funding Application
(800) 574 – 6320
Request a call back
Write us
info@mentorcapital.com
5964 Campus Court
Plano, TX 75093
Home Press

Press

  • Mentor Capital Enters Medical Marijuana Field to Combat Cancer Wasting

    • Sep 30, 2013
    gfarmalabs

    SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (OTC Markets: MNTR) announced that it has initiated investment in the Medical Marijuana market. “The ‘munchies’ are a godsend to cancer sufferers who just stop eating food that tastes like wood and leaves them nauseous,” explains Mentor CEO, Chester Billingsley. “In the days of clans and caves, elders…

    read more
  • Mentor Capital, Inc. Funds Completion of 12.5% Stock Buyback

    • Sep 5, 2013
    gfarmalabs

    SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (OTCMKTS:MNTR) has deposited funds with its broker to complete the final tranche of its multi-year stock repurchase program. In 2008, Mentor Capital, Inc. committed to the repurchase of 12.5% of its then outstanding common stock and is positioned to wrap-up that stock buy-back now. The purpose of…

    read more
  • Mentor Capital Cancer Immunotherapy Index Gains 31% During First Half of 2013

    • Jul 19, 2013
    gfarmalabs

    SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 30.6% during the first half of 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the first half the…

    read more
  • Mentor Capital Cancer Immunotherapy Index Gains 32% YTD and Adds Second Generation Firms for 2013

    • Mar 15, 2013
    gfarmalabs

    SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that for 2013 it has added Galena Biopharma Corporation (NASDAQ:GALE), NewLink Genetics Corporation (NASDAQ:NLNK), Vical Incorporated (NASDAQ:VICL) and Inovio Pharmaceuticals, Inc. (NYSE MKT:INO) to its proprietary Cancer Immunotherapy Index. The four firms and others in the Index…

    read more
  • Mentor Capital Cancer Immunotherapy Index Posts 11% Annual Loss in 2012 and Adds Companies for 2013

    • Feb 19, 2013
    gfarmalabs

    SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index declined (-10.9%) during 2012. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For 2012 the biotech indices averaged a 32.7%…

    read more
  • Mentor Capital Cancer Immunotherapy Index Gains 47% During First Quarter

    • Apr 17, 2012
    gfarmalabs

    SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index has appreciated 47.3% during the first quarter of 2012. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the first…

    read more
  • Mentor Capital Reports Mid-Year Profits for 2011

    • Oct 6, 2011
    gfarmalabs

    SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (OTC Markets: MNTR) today reported financial results for the semi-annual period ending June 30, 2011. The company announced earnings of $0.04 per basic and diluted share for the six-month period. The six months of earnings, which calculates to an $0.08 per share annualized rate, follows the $0.09 per basic share …

    read more
  • Mentor Capital Cancer Immunotherapy Index Outpaces Biotechs on Second Anniversary

    • Jul 12, 2011
    gfarmalabs

    SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index has appreciated 85.30% during the twenty-four months since its creation on July 10, 2009. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE…

    read more
  • Mentor Capital Cancer Immunotherapy Index Gains on Medicare Advisory Committee Approval of $93,000 Provenge Immunotherapy Treatment by Dendreon for Prostate Cancer

    • Nov 24, 2010
    gfarmalabs

    SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports correlated gains across the 10 trading companies of the Mentor Capital Cancer Immunotherapy Index with the recent 6.6% one-day price appreciation of Index pioneer and market leader, Dendreon (NASDAQ:DNDN). The Dendreon price appreciation follows the Medicare Evidence Development &…

    read more
  • Mentor Capital Takes Investment Position in Each of 10 Cancer Immunotherapy Index Companies

    • Jan 19, 2010
    gfarmalabs

    SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) has completed the set-up and initial funding of the Cancer Immunotherapy Index Fund. Through the CII Fund, Mentor Capital has now taken an initial equity position in each of the ten companies that make up Mentor Capital's proprietary Cancer Immunotherapy Index. The equally weighted CI Index was…

    read more
How can we help you?

The best way to contact us is to submit a business inquiry online. Your inquiry will be directed to the appropriate department, and someone will be in touch!

 
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8

    Navigation

    • Home
    • Contact
    • Safe Harbor Statement
    • Privacy Policy
    • Disclaimer
    • Sitemap

    Mentor Capital, Inc

    Mentor Capital, Inc. (MNTR) is a publicly traded operating company that provides owners and pre-IPO companies with access to liquidity and funding from both public sources and the divestiture of legacy assets.

    Subscribe

    Recent News

    • Mentor Capital Harvests Half of Market Value in Cash from Side Investments and Reports 30% Q3 Sales Growth Nov 21, 2022
    • Mentor Capital Posts 1 Cent Net Profit on a 4 Cent Share Price in 10-Q Aug 15, 2022
    • Mentor Capital Posts 40% Annual Revenue Gain in 10-Q May 16, 2022
    Copyright © 2023 Mentor Capital, Inc. All rights reserved.